Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 44.71% is 106% above its 5-year average of 21.74%, near the high end of its 5-year range (-95.03%–59.26%).
14.65% below its 12-month average of 52.39%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 59.10%.
GROSS MARGIN
44.71%
GROSS MARGIN AVG TTM
52.39%
GROSS MARGIN AVG 3Y
32.44%
GROSS MARGIN AVG 5Y
21.74%
GROSS MARGIN AVG 10Y
-15.93%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-14.65%
CURRENT VS 3Y AVG
+37.83%
CURRENT VS 5Y AVG
+105.68%
CURRENT VS 10Y AVG
+380.62%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+8.05%
vs the sector median at left
Senseonics Holdings, Inc.
Market Cap
$414.61M
Gross Margin
44.71%
TTM Avg
52.39%
3Y Avg
32.44%
5Y Avg
21.74%
Market Cap
$415.42M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$415.45M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$411.94M
Gross Margin
20.56%
TTM Avg
22.27%
3Y Avg
19.63%
5Y Avg
19.86%
Market Cap
$407.54M
Gross Margin
0.00%
TTM Avg
-125.52%
3Y Avg
-62.76%
5Y Avg
-41.84%
Market Cap
$422.98M
Gross Margin
61.77%
TTM Avg
80.89%
3Y Avg
90.44%
5Y Avg
-1369.52%
Market Cap
$406.82M
Gross Margin
68.83%
TTM Avg
69.91%
3Y Avg
69.67%
5Y Avg
69.68%
Market Cap
$427.50M
Gross Margin
73.89%
TTM Avg
76.35%
3Y Avg
-237.05%
5Y Avg
-138.49%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Senseonics Holdings, Inc. (SENS) | $414.61M | 44.71% | 52.39% | 32.44% | 21.74% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $415.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $415.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| Strata Critical Medical, Inc. (SRTA)vs › | $411.94M | 20.56% | 22.27% | 19.63% | 19.86% |
| Neurogene Inc. (NGNE)vs › | $407.54M | 0.00% | -125.52% | -62.76% | -41.84% |
| Rezolute, Inc. (RZLT)vs › | $408.01M | 0.00% | 0.00% | 0.00% | 0.00% |
| Prothena Corporation plc (PRTA)vs › | $422.98M | 61.77% | 80.89% | 90.44% | -1369.52% |
| Myriad Genetics, Inc. (MYGN)vs › | $406.82M | 68.83% | 69.91% | 69.67% | 69.68% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $427.50M | 73.89% | 76.35% | -237.05% | -138.49% |
| Shoulder Innovations, Inc. (SI)vs › | $401.91M | 77.34% | 76.74% | 77.57% | 77.57% |
Gross Margin
44.7%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 59.10% |
| 2026-03-31 | 59.26% |
| 2025-12-31 | 53.79% |
| 2025-09-30 | 42.84% |
| 2025-06-30 | 46.94% |
| 2025-03-31 | 24.05% |
| 2024-12-31 | 47.62% |
| 2024-09-30 | -95.03% |
| 2024-06-30 | 6.13% |
| 2024-03-31 | 6.64% |
| 2023-12-31 | 13.56% |
| 2023-09-30 | 19.22% |
| 2023-06-30 | 10.11% |
| 2023-03-31 | 10.01% |
| 2022-12-31 | 11.11% |
| 2022-09-30 | 16.36% |
| 2022-06-30 | 22.19% |
| 2022-03-31 | 21.24% |
| 2021-12-31 | -12.05% |
| 2021-09-30 | -35.28% |
| 2021-06-30 | 11.92% |
| 2021-03-31 | 18.48% |
| 2020-12-31 | 66.31% |
| 2020-09-30 | 108.87% |
| 2020-06-30 | -437.93% |
| 2020-03-31 | -54538.89% |
| 2019-12-31 | -92.10% |
| 2019-09-30 | -77.33% |
| 2019-06-30 | -98.83% |
| 2019-03-31 | -96.70% |
| 2018-12-31 | -69.38% |
| 2018-09-30 | -50.10% |
| 2018-06-30 | -5.96% |
| 2018-03-31 | -12.29% |
| 2017-12-31 | -38.95% |
| 2017-09-30 | -41.01% |
| 2017-06-30 | -110.57% |
| 2017-03-31 | -88.97% |
| 2016-12-31 | -85.51% |
| 2016-09-30 | -208.11% |
| 2016-06-30 | -78.95% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 100.00% |
| 2015-03-31 | 100.00% |
| 2014-12-31 | 0.00% |
| 2014-09-30 | 0.00% |
